^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ITK inhibitor

    Related drugs:
    18h
    ITK-targeted immune remodeling enhanced the efficacy of anti-CD19 CAR-T cell therapy. (PubMed, Cell Death Discov)
    Importantly, the modulation of transcription factors like TOX and TCF1 suggested a delay in T cell exhaustion and maintenance of effector functions. These findings provide a compelling rationale for the integration of clinical stage ITK inhibitor soquelitinib with CAR-T therapy, highlighting its potential to improve treatment outcomes in hematological malignancies and solid tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • GZMB (Granzyme B)
    |
    soquelitinib (CPI-818)
    1d
    SIERRA1: Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD (clinicaltrials.gov)
    P2, N=200, Recruiting, Corvus Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    soquelitinib (CPI-818)
    4d
    SIERRA1: Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Corvus Pharmaceuticals, Inc.
    New P2 trial
    |
    soquelitinib (CPI-818)
    23d
    Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, Corvus Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Feb 2026 | Trial primary completion date: Oct 2025 --> Feb 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    soquelitinib (CPI-818)
    1m
    Safety, tolerability, and preliminary efficacy of CPI-818 in the treatment of moderate to severe atopic dermatitis (ChiCTR2500110450)
    P1/2, N=123, Recruiting, Shanghai Skin Disease Hospital; Angel Pharmaceutical | Not yet recruiting --> Recruiting
    Enrollment open
    |
    soquelitinib (CPI-818)
    4ms
    Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling. (PubMed, Cell Signal)
    Finally, we found that selective, partial inhibition of Itk using Soquelitinib reduced basal CD69 expression in CAR-Jurkat cells while maintaining their ability to activate in response to antigen. These data suggest that TCRζ determines the pY signalling profile and that Itk drives basal activation of CD19-CAR Jurkats, which may impact evaluation of new CAR designs in CAR-Jurkat screens.
    Journal • IO biomarker
    |
    CD47 (CD47 Molecule) • CD69 (CD69 Molecule) • PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22)
    |
    soquelitinib (CPI-818)
    4ms
    Safety, tolerability, and preliminary efficacy of CPI-818 in the treatment of moderate to severe atopic dermatitis (ChiCTR2500110450)
    P1/2, N=123, Not yet recruiting, Shanghai Skin Disease Hospital; Angel Pharmaceutical
    New P1/2 trial
    |
    soquelitinib (CPI-818)
    8ms
    Inclusion of the ζ-chain drives phosphotyrosine signalling in CD19-CAR T cells. (PubMed, bioRxiv)
    Finally, we find that selective, partial inhibition of Itk using Soquelitinib reduces basal CD69 expression in Jurkat CAR T cells while maintaining their ability to activate in response to antigen. Our data suggest that the ζ-chain determines the pY signalling profile of CD19-CAR Jurkat T cells and that Itk may drive antigen-independent CD19-CAR activation.
    Journal
    |
    CD69 (CD69 Molecule) • PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22)
    |
    soquelitinib (CPI-818)
    9ms
    Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD (clinicaltrials.gov)
    P1, N=72, Recruiting, Corvus Pharmaceuticals, Inc. | Trial completion date: Apr 2025 --> Nov 2025 | Trial primary completion date: Apr 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    soquelitinib (CPI-818)
    10ms
    Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=14, Completed, Aclaris Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    11ms
    Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (clinicaltrials.gov)
    P3, N=150, Recruiting, Corvus Pharmaceuticals, Inc. | Trial completion date: Sep 2027 --> Jul 2028 | Trial primary completion date: Feb 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Beleodaq (belinostat) • Folotyn (pralatrexate) • soquelitinib (CPI-818)
    12ms
    Study of ATI-2138 in Adult Participants with Moderate to Severe Atopic Dermatitis (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, Aclaris Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed